Literature DB >> 2453226

Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects.

P V Parab1, W A Ritschel, D E Coyle, R V Gregg, D D Denson.   

Abstract

The pharmacokinetic properties of hydromorphone in healthy young male subjects were studied after i.v., peroral, and rectal administration. After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1. The absolute bioavailability after peroral administration was 50.7 +/- 29.8 per cent, and that after rectal administration was 33 +/- 22 per cent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453226     DOI: 10.1002/bod.2510090207

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.

Authors:  Kelly E Dunn; Bruna Brands; David C Marsh; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2017-12-21       Impact factor: 4.530

Review 3.  Patient-controlled analgesia in the management of postoperative pain.

Authors:  Mona Momeni; Manuela Crucitti; Marc De Kock
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 5.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  External Validation of a Recently Developed Population Pharmacokinetic Model for Hydromorphone During Postoperative Pain Therapy.

Authors:  Harald Ihmsen; Doris Rohde; Jürgen Schüttler; Christian Jeleazcov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

7.  Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Authors:  George A Davis; Anita C Rudy; Sanford M Archer; Daniel P Wermeling; Patrick J McNamara
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

Review 9.  Hydromorphone Prescription for Pain in Children-What Place in Clinical Practice?

Authors:  Frédérique Rodieux; Anton Ivanyuk; Marie Besson; Jules Desmeules; Caroline F Samer
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

10.  Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone.

Authors:  Gayatri Sathyan; Emily Xu; John Thipphawong; Suneel K Gupta
Journal:  BMC Clin Pharmacol       Date:  2007-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.